Sanofi, Novo Spar In Insulin Pen Patent Suit—Again

Law360, New York (October 26, 2007, 12:00 AM EDT) -- Sanofi-Aventis has bulwarked its defenses against Novo Nordisk A/S and stepped up its demands for relief in their insulin pen spat with a dozen counterclaims, citing a licensing deal it said prevented Novo from suing and pointing to the company's history of crying wolf with patent suits it eventually withdraws.

Novo's suit, filed in the U.S. District Court for the District of New Jersey, accuses Sanofi's SoloStar pen of infringing its patent, U.S. Patent Number 7,241,278, for FlexPen, the top-selling insulin injection device in the U.S....
To view the full article, register now.